News

OpGen Unyvero Hospitalized Pneumonia (HPN) Panel Rapidly Identifies Bacterial Coinfections in COVID-19 Pneumonia

19-JUN-2020 (https://www.infectiousdiseaseadvisor.com/) The Unyvero HPN panel provides comprehensive diagnostic information to clinicians in less than 5 hours, with only minutes of actual hands-on time. The Unyvero Hospitalized Pneumonia (HPN) panel (OpGen, Inc., Gaithersburg, MD) identifies bacterial coinfections in <5 hours in hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, according to a news release on…

Read More

OpGen Subsidiary Curetis GmbH and Karolinska Institute Collaborate in Study of Bacterial Co-Infections in COVID-19 Pneumonia Patients

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, April 21, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today the start of an investigator initiated collaboration with Karolinska Institutet, Sweden, to identify bacterial co-infections in patients admitted to the…

Read More

OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing (NGS) Based Antibiotic Susceptibility Testing (AST) in Multi-Center Study

VIENNA, Austria and GAITHERSBURG, Md., April 16, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that a study on the feasibility and potential of antibiotic susceptibility testing and bacterial pathogen identification using next-generation sequencing (NGS)…

Read More

Curetis and OpGen Complete Business Combination

Amsterdam, The Netherlands, and Holzgerlingen, Germany, April 01, 2020, 10:00 pm CET – Curetis N.V. (in liquidation) (the “Company”) today announced that the business combination between the Company and OpGen Inc. (“OpGen”) has successfully been completed. The signing of the German transfer agreement implementing the transfer of 100% of the shares in Curetis GmbH to…

Read More

OpGen Announces Shareholder Approval for Business Combination with Curetis

GAITHERSBURG, Md., March 30, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that, following its Special Meeting of Shareholders held March 30, 2020, OpGen shareholders overwhelmingly voted to approve the proposed business combination with Curetis…

Read More

Curetis Begins Offering BGI’s CE-IVD Rapid Test Kit for Coronavirus in Europe

Holzgerlingen, Germany, March 16, 2020, 08:00 am CET – Curetis N.V. (the “Company” and together with its subsidiaries “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that it starts offering a CE-IVD certified real-time PCR test kit for SARS-CoV2 (also known as 2019-nCov), the causal pathogen of Corona Virus Disease 2019 (Covid-19). The…

Read More

Curetis N.V. Reports Results of the Extraordinary General Meeting

Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 10, 2020, 14:15 pm CET – Curetis N.V. (the “Company” and together with its subsidiaries “Curetis”), a developer of next-level molecular diagnostic solutions, today reported the results of its Extraordinary General Meeting (the “EGM”) held in Schiphol today, March 10, 2020. Shareholders adopt all…

Read More

Epigenomics Request Triggers Centers for Medicare and Medicaid Services (CMS) Plan To Cover Colorectal Cancer Blood-Based Biomarker Tests

03 Mar 2020 – MedTech Insights – The US Centers for Medicare and Medicaid Services is considering a national coverage determination for a blood-based biomarker screening test for colorectal cancer after receiving a request for a national coverage determination from Epigenomics for its Epi proColon assay. The US Centers for Medicare and Medicaid Services on…

Read More

Centers for Medicare & Medicaid Services (CMS) Open National Coverage Determination (NCD) Review Process for Epi proColon

Berlin, 28.02.2020– Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that the Centers for Medicare & Medicaid Services (CMS) have opened the National Coverage Determination (NCD) review of Epi proColon, Epigenomics’ blood test for colorectal cancer screening. This means that according to the statutes, a decision on CMS’s reimbursement of Epi proColon…

Read More